EuroBiotech: More Articles of Note


> Kiadis Pharma warned investors it expects the European Medicines Agency to reject its request for conditional approval of ATIR101 in hematopoietic stem cell transplant patients. The setback would delay approval until at least 2021, when an interim analysis of a phase 3 trial is due to take place. Release 

> A phase 2 trial of Bavarian Nordic’s CV301 in combination with Roche’s checkpoint inhibitor failed to clear the efficacy threshold for advancement. Bavarian Nordic responded by shifting the focus of its cancer strategy. Statement 

> Idorsia delayed two clinical readouts. Results from a phase 3 trial of daridorexant in insomnia slipped from the first half of 2020 to the middle of the year. Slow enrollment in a phase 3 trial of lucerastat in Fabry disease caused that readout to slip, too. Release 

Virtual Roundtable

ASCO Explained: Expert predictions and takeaways from the world's biggest cancer meeting

Join FiercePharma for our ASCO pre- and post-show webinar series. We'll bring together a panel of experts to preview what to watch for at ASCO. Cancer experts will highlight closely watched data sets to be unveiled at the virtual meeting--and discuss how they could change prescribing patterns. Following the meeting, we’ll do a post-show wrap up to break down the biggest data that came out over the weekend, as well as the implications they could have for prescribers, patients and drugmakers.

> Abivax presented 12-month safety and efficacy data on ABX464 in ulcerative colitis. Statement 

> Ipsen delayed its planned FDA filing for approval of palovarotene until the first quarter of 2020. The delay stems from “the processing of additional supportive data.” Release 

> Vivoryon Therapeutics raised €43 million ($48 million). The money will support a phase 2 Alzheimer’s disease trial. Statement 

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.